Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$26.26 USD

26.26
35,671,103

+0.26 (1.00%)

Updated Apr 22, 2024 04:00 PM ET

After-Market: $26.25 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (217 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Rises Higher Than Market: Key Facts

Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Why the Market Dipped But Pfizer (PFE) Gained Today

Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.

Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International

UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for UnitedHealth, Pfizer & BlackRock

Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).

Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal

Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.

Pfizer (PFE) Declines More Than Market: Some Information for Investors

In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Pfizer (PFE) Stock Moves -0.11%: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $27.72, marking a -0.11% move from the previous day.

Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study

Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $27.43, moving +0.26% from the previous trading session.

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Kinjel Shah headshot

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.

Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

GSK Outperforms Industry on Strength in Key Drugs & Vaccines

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.

Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Pfizer (PFE) closed at $27.63 in the latest trading session, marking a -0.32% move from the prior day.

Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%

Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.

The Zacks Analyst Blog Highlights Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer

Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer are included in this Analyst Blog.